Q1 2025 Management View CEO Linda Marban reviewed progress on the Biologics License Application (BLA) for deramiocel, targeting full approval for treating Duchenne muscular dystrophy (DMD) ...

Daré will host a conference call and live webcast today, May 13, 2025, at 4:30 p.m. Eastern Time to review financial results ...

Discover Q1 2025 earnings insights from Cellectar Biosciences (CLRB), focusing on regulatory progress for iopofosine I 131, strategic alternatives, ...

Q1 2025 Management View CEO Dan Barber highlighted that the company is now over a month into the FDA review for Anaphylm ...

Welcome to FibroGen first quarter 2025 earnings conference call. (Operator Instructions). Please be advised today's conference is being recorded. I would not like to end the conference over to your ...

Discover REGENXBIO's Q1 2025 milestones, including FDA updates, pivotal trial progress, and commercial readiness for gene therapies addressing rare ...

Vinay Prasad oversees vaccines, gene therapies and the blood supply. His views raise alarms for pharmaceutical companies and ...

Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $185 million, a $25 million increase from initial guidance Net cash held in China at closing now esti ...

Zack Armen; Head of Investor Relations, Corporate Development; Agenus Inc. Garo Armen; Chairman of the Board, Chief Executive Officer, Co-Founder; Agenus Inc. Richar ...